EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

Ellen James, David Erritzoe, Tiffanie Benway, Zelah Joel, Christopher Timmermann, Meghan Good, Claudio Agnorelli, Brandon M Weiss, Tommaso Barba, Graham Campbell, Michelle Baker Jones, Charlotte Hughes und 3 weitere

Frontiers in Psychiatry · 11.01.2024 · 14

DOI: 10.3389/fpsyt.2023.1305796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 11.01.2024. Verfasst von Ellen James und 14 weiteren Autor:innen. Beteiligte Einrichtung: Small Pharma Ltd., London, United Kingdom. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Due to their potential impact on mood and wellbeing there has been increasing interest in the potential of serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) in the treatment of major depressive disorder (MDD).

Aim

The aim of Part A of this study was to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) profile of escalating doses of SPL026 (DMT fumarate) in psychedelic-naïve healthy participants to determine a dose for administration to patients with MDD in the subsequent Phase 2a part of the trial (Part B: not presented in this manuscript).

Methods

In the Phase 1, randomized, double-blind, placebo-controlled, parallel-group, single dose-escalation trial, psychedelic-naïve participants were randomized to placebo ( n = 8) or four different escalating doses [9, 12, 17 and 21.5 mg intravenously (IV)] of SPL026 ( n = 6 for each dose) together with psychological support from 2 therapy team members. PK and acute (immediately following dosing experience) psychometric measures [including mystical experience questionnaire (MEQ), ego dissolution inventory (EDI), and intensity rating visual analogue scale (IRVAS)] were determined. Additional endpoints were measured as longer-term change from baseline to days 8, 15, 30 and 90. These measures included the Warwick and Edinburgh mental wellbeing scale and Spielberger’s state-trait anxiety inventory.

Results

SPL026 was well tolerated, with an acceptable safety profile, with no serious adverse events. There was some evidence of a correlation between maximum plasma concentration and increased IRVAS, MEQ, and EDI scores. These trends are likely to require confirmation in a larger sample size. Using the analysis of the safety, tolerability, PD, PK results, doses of 21.5 mg SPL026 were the most likely to provide an intense, tolerated experience.

Conclusion

Based on the data obtained from this part of the trial, a dose of 21.5 mg SPL026 given as a 2-phase IV infusion over 10 min (6 mg/5 min and 15.5 mg/5 min) was selected as the dose to be taken into patients in Part B (to be presented in a future manuscript). Clinical trial registration: www.clinicaltrials.gov , identifier NCT04673383; https://www.clinicaltrialsregister.eu , identifier 2020-000251-13; https://www.isrctn.com/ , identifier ISRCTN63465876.

Schlagwörter

Stichwörter der Autor:innen

dimethyltryptaminemajor depressive disorderpharmacodynamicpsychedelicsafetytolerability

Autor:innen und Institutionen

  • Small Pharma Ltd., London, United Kingdom.
  • The Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom.
  • Hammersmith Medicines Research, London, United Kingdom.

Zitieren

APA

James, E., Erritzoe, D., Benway, T., Joel, Z., Timmermann, C., Good, M., Agnorelli, C., Weiss, B. M., Barba, T., Campbell, G., Baker Jones, M., Hughes, C., Topping, H., Boyce, M., & Routledge, C. (2024). Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1305796

Vancouver

James E, Erritzoe D, Benway T, Joel Z, Timmermann C, Good M, et al. Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial. Frontiers in Psychiatry. 2024;14. doi:10.3389/fpsyt.2023.1305796

BibTeX
@article{James2024,
  author = {James, Ellen and Erritzoe, David and Benway, Tiffanie and Joel, Zelah and Timmermann, Christopher and Good, Meghan and Agnorelli, Claudio and Weiss, Brandon M and Barba, Tommaso and Campbell, Graham and Baker Jones, Michelle and Hughes, Charlotte and Topping, Helen and Boyce, Malcolm and Routledge, Carol},
  title = {Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial},
  journal = {Frontiers in Psychiatry},
  year = {2024},
  volume = {14},
  doi = {10.3389/fpsyt.2023.1305796}
}
Kostenlos starten →